Sarepta Therapeutics, Inc.
SRPT • NASDAQ
Sarepta Therapeutics, Inc. is a biotechnology company in the healthcare sector trading on NASDAQ, led by CEO Douglas S. Ingram, with a market cap of $1.8B.
CEODouglas S. Ingram
Market Cap$1.8B
Biotechnology
Healthcare
Employees1.3K
Websitesarepta.com
Country
United States of America
Next Earnings
Upcoming earnings announcement for Sarepta Therapeutics, Inc.
Date
Tuesday, May 5, 2026 (in 3 months)
Timing
After Market Close (4:00 PM New York)
Fiscal Period
Q1 2026
EPS Estimate
$0.43
Revenue Estimate
$376.9M
Earnings History
Past 11 earnings reports for Sarepta Therapeutics, Inc.
| Date | Period | EPS | EPS Surprise | Revenue | Rev. Surprise | Filing |
|---|---|---|---|---|---|---|
| Nov 3, 2025 | Q3 2025 | -$0.13Est: -$0.46 | +71.7% | $399.4MEst: $343.3M | +16.3% |  10-Q |
| Aug 6, 2025 | Q2 2025 | $2.02Est: $1.01 | +100.0% | $611.1MEst: $530.4M | +15.2% | 10-Q |
| May 6, 2025 | Q1 2025 | -$3.42Est: -$0.65 | -426.2% | $744.9MEst: $684.1M | +8.9% | 10-Q |
| Feb 26, 2025 | Q4 2024 | $1.90Est: $1.90 | 0.0% | $658.4MEst: $627.6M | +4.9% | 10-K |
| Nov 6, 2024 | Q3 2024 | $0.62Est: $0.37 | +67.6% | $467.2MEst: $409.3M | +14.1% | 10-Q |
| Aug 7, 2024 | Q2 2024 | $0.44Est: $0.02 | +2100.0% | $362.9MEst: $396.3M | -8.4% | 10-Q |
| May 1, 2024 | Q1 2024 | $0.73Est: -$0.07 | +1142.9% | $413.5MEst: $373.3M | +10.8% | 10-Q |
| Feb 28, 2024 | Q4 2023 | $0.82Est: $0.01 | +8100.0% | $396.8MEst: $385.8M | +2.8% | 10-K |
| Nov 1, 2023 | Q3 2023 | $0.37Est: -$1.32 | +128.0% | $331.8MEst: $288.5M | +15.0% | — |
| Aug 2, 2023 | Q2 2023 | -$0.85Est: -$1.89 | +55.0% | $261.2MEst: $264.5M | -1.2% | 10-Q |
| May 2, 2023 | Q1 2023 | -$0.97Est: -$1.38 | +29.7% | $253.5MEst: $242.0M | +4.8% | 10-Q |